INFOGRAPHIC: Immuno-Oncology Targets And Deal Trends
Executive Summary
Immuno-oncology R&D is surging, though most programs still are in preclinical studies or early clinical trials. Even so, dealmaking is thriving and generating lucrative terms compared with cancer deals in general as big pharma and large biotech companies look for the safest and most effective IO drug combinations.